All In Biotech

BLA 761078 · Emd Serono INC

Bavencio

Avelumab · Intravenous

Accelerated approvalPriority review

Last checked: Nov 20, 2026Latest source record: May 9, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

May 9, 2017

Approved uses

1

Original approval plus efficacy supplements

Registered trials

269

20 Phase 3, 20 recruiting

FAERS reports

4,102

3,741 serious, 946 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 9, 2017 Original approval · Type 9 - New indication submitted as distinct BLA, consolidated · priority review Accelerated approvalLabelMedication GuideLetter
1 products under this application
  • BAVENCIO · AVELUMAB 20MG/ML · INJECTABLE, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Avelumab" as an intervention, any sponsor and status, largest first.

All 269 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • disease progression386
  • death377
  • off label use239
  • diarrhoea171
  • pyrexia150
  • infusion related reaction148
  • fatigue136
  • neoplasm progression125
  • dyspnoea111
  • nausea110
  • chills107
  • hypertension107

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201613
2017216
2018389
2019433
2020446
2021565
2022577
2023489
2024438
2025320
2026216

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Bavencio (Avelumab)

2024 spending

$2.0M

Beneficiaries

28

170 claims

Per beneficiary

$73,041

$190.25 per unit

View as table
YearSpending
2020$793,201
2021$1,567,112
2022$1,954,833
2023$2,230,421
2024$2,045,161

Part B: Bavencio (Avelumab) · HCPCS J9023

2024 spending

$97.9M

Beneficiaries

1,062

12,217 claims

Per beneficiary

$92,191

2024 ASP limit $93.70 per unit

View as table
YearSpending
2020$44,264,265
2021$79,095,180
2022$111,862,815
2023$123,396,723
2024$97,907,150

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 301 on PubMed

Sponsor: Emd Serono INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.